122 related articles for article (PubMed ID: 21098255)
1. Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers.
Serra DB; Sun H; Karwowska S; Praestgaard J; Halabi A; Stein DS
Antimicrob Agents Chemother; 2011 Feb; 55(2):473-7. PubMed ID: 21098255
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and exposure-response of albinterferon alfa-2b.
Riggs MM; Bergsma TT; Rogers JA; Gastonguay MR; Subramanian GM; Chen C; Devalaraja M; Corey AE; Sun H; Yu J; Stein DS
J Clin Pharmacol; 2012 Apr; 52(4):475-86. PubMed ID: 21551316
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.
Pianko S; Zeuzem S; Chuang WL; Foster GR; Sarin SK; Flisiak R; Lee CM; Andreone P; Piratvisuth T; Shah S; Sood A; George J; Gould M; Komolmit P; Thongsawat S; Tanwandee T; Rasenack J; Li Y; Pang M; Yin Y; Feutren G; Jacobson IM;
J Viral Hepat; 2012 Sep; 19(9):623-34. PubMed ID: 22863266
[TBL] [Abstract][Full Text] [Related]
4. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
Nelson DR; Benhamou Y; Chuang WL; Lawitz EJ; Rodriguez-Torres M; Flisiak R; Rasenack JW; Kryczka W; Lee CM; Bain VG; Pianko S; Patel K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG;
Gastroenterology; 2010 Oct; 139(4):1267-76. PubMed ID: 20600017
[TBL] [Abstract][Full Text] [Related]
5. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.
Nelson DR; Rustgi V; Balan V; Sulkowski MS; Davis GL; Muir AJ; Lambiase LR; Dickson RC; Weisner RH; Fiscella M; Cronin PW; Pulkstenis E; McHutchison JG; Subramanian GM
Clin Gastroenterol Hepatol; 2009 Feb; 7(2):212-8. PubMed ID: 19061971
[TBL] [Abstract][Full Text] [Related]
6. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C.
Rustgi VK
Curr Med Res Opin; 2009 Apr; 25(4):991-1002. PubMed ID: 19275518
[TBL] [Abstract][Full Text] [Related]
7. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
Zeuzem S; Sulkowski MS; Lawitz EJ; Rustgi VK; Rodriguez-Torres M; Bacon BR; Grigorescu M; Tice AD; Lurie Y; Cianciara J; Muir AJ; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG;
Gastroenterology; 2010 Oct; 139(4):1257-66. PubMed ID: 20600013
[TBL] [Abstract][Full Text] [Related]
8. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
Foster GR; Zeuzem S; Pianko S; Sarin SK; Piratvisuth T; Shah S; Andreone P; Sood A; Chuang WL; Lee CM; George J; Gould M; Flisiak R; Jacobson IM; Komolmit P; Thongsawat S; Tanwandee T; Rasenack J; Sola R; Messina I; Yin Y; Cammarata S; Feutren G; Brown KK
J Viral Hepat; 2013 Apr; 20(4):e115-23. PubMed ID: 23490379
[TBL] [Abstract][Full Text] [Related]
9. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction.
Gupta SK; Pittenger AL; Swan SK; Marbury TC; Tobillo E; Batra V; Sack M; Glue P; Jacobs S; Affrime M
J Clin Pharmacol; 2002 Oct; 42(10):1109-15. PubMed ID: 12362925
[TBL] [Abstract][Full Text] [Related]
10. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
Zeuzem S; Yoshida EM; Benhamou Y; Pianko S; Bain VG; Shouval D; Flisiak R; Rehak V; Grigorescu M; Kaita K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG
Hepatology; 2008 Aug; 48(2):407-17. PubMed ID: 18666223
[TBL] [Abstract][Full Text] [Related]
11. Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.
Bain VG; Kaita KD; Marotta P; Yoshida EM; Swain MG; Bailey RJ; Patel K; Cronin PW; Pulkstenis E; McHutchison JG; Subramanian GM
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):701-6. PubMed ID: 18467185
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
Brennan BJ; Xu ZX; Grippo JF
Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications.
Rostaing L; Chatelut E; Payen JL; Izopet J; Thalamas C; Ton-That H; Pascal JP; Durand D; Canal P
J Am Soc Nephrol; 1998 Dec; 9(12):2344-8. PubMed ID: 9848789
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
Miyachi N; Zagrijtschuk O; Kang L; Yonezu K; Qin A
Clin Drug Investig; 2021 Apr; 41(4):391-404. PubMed ID: 33725322
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
16. Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection.
Colvin RA; Tanwandee T; Piratvisuth T; Thongsawat S; Hui AJ; Zhang H; Ren H; Chen PJ; Chuang WL; Sobhonslidsuk A; Li R; Qi Y; Praestgaard J; Han Y; Xu J; Stein DS;
J Gastroenterol Hepatol; 2015 Jan; 30(1):184-91. PubMed ID: 24995515
[TBL] [Abstract][Full Text] [Related]
17. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
Khakoo S; Glue P; Grellier L; Wells B; Bell A; Dash C; Murray-Lyon I; Lypnyj D; Flannery B; Walters K; Dusheiko GM
Br J Clin Pharmacol; 1998 Dec; 46(6):563-70. PubMed ID: 9862245
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
Osinusi A; Bon D; Nelson A; Lee YJ; Poonia S; Shivakumar B; Cai SY; Wood B; Haagmans B; Lempicki R; Herrmann E; Sneller M; Polis M; Masur H; Kottilil S
J Med Virol; 2014 Feb; 86(2):177-85. PubMed ID: 24166150
[TBL] [Abstract][Full Text] [Related]
19. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers.
Garcia-Garcia I; Gonzalez-Delgado CA; Valenzuela-Silva C; Hernandez-Bernal F; Ferrero-Bibilonia J; Soto-Hernandez R; Cervantes-Llano M; Ducongé J; Correa-Fernandez A; Olivera-Ruano L; Lopez-Saura P
Drugs R D; 2004; 5(5):271-80. PubMed ID: 15357626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
